Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
727 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05338970 | HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy | active not recruiting | Phase 3 | 586 | Daiichi SankyoINDUSTRY | 21 | Aug 27, 2026 | clinicaltrials |
| NCT00066690 | Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer(SOFT) | completed | Phase 3 | 3,066 | ETOP IBCSG Partners FoundationNETWORK |
| 3 |
| Aug 26, 2026 |
| clinicaltrials |
| NCT01652469 | Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.(EMPHASIS) | completed | Phase 3 | 81 | ETOP IBCSG Partners FoundationNETWORK | 12 | Aug 26, 2026 | clinicaltrials |
| NCT04656652 | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | active not recruiting | Phase 3 | 605 | Daiichi SankyoINDUSTRY | 26 | Aug 26, 2026 | clinicaltrials |
| NCT05328908 | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer(RELATIVITY-123) | terminated | Phase 3 | 769 | Bristol-Myers SquibbINDUSTRY | 22 | Aug 26, 2026 | clinicaltrials |
| NCT05456191 | A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)(ASC4START) | active not recruiting | Phase 3 | 568 | Novartis PharmaceuticalsINDUSTRY | 24 | Aug 26, 2026 | clinicaltrials |
| NCT05625399 | A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma(RELATIVITY-127) | active not recruiting | Phase 3 | 579 | Bristol-Myers SquibbINDUSTRY | 19 | Aug 26, 2026 | clinicaltrials |
| NCT04039607 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma(CheckMate 9DW) | completed | Phase 3 | 732 | Bristol-Myers SquibbINDUSTRY | 26 | Aug 25, 2026 | clinicaltrials |
| NCT04770896 | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab(IMbrave251) | active not recruiting | Phase 3 | 557 | Hoffmann-La RocheINDUSTRY | 28 | Aug 25, 2026 | clinicaltrials |
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC(ALKAZAR) | recruiting | Phase 3 | 450 | Nuvalent Inc.INDUSTRY | 29 | Aug 25, 2026 | clinicaltrials |
| NCT02991482 | PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma(PROMISE-meso) | completed | Phase 3 | 144 | ETOP IBCSG Partners FoundationNETWORK | 3 | Aug 24, 2026 | clinicaltrials |
| NCT05183035 | Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | recruiting | Phase 3 | 130 | PedAL BCU, LLCOTHER | 20 | Aug 24, 2026 | clinicaltrials |
| NCT07782112 | Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)(ESCALATE-RT) | not yet recruiting | Phase 3 | 140 | Ente Ospedaliero Cantonale, BellinzonaOTHER | 3 | Aug 24, 2026 | clinicaltrials |
| NCT06499285 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | recruiting | Phase 3 | 225 | TakedaINDUSTRY | 26 | Aug 21, 2026 | clinicaltrials |
| NCT03007147 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 352 | Children's Oncology GroupNETWORK | 19 | Aug 19, 2026 | clinicaltrials |
| NCT06556563 | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma(EF-41) | recruiting | Phase 3 | 741 | NovoCure GmbHINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT07682558 | Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management(NoDoubt) | not yet recruiting | Phase 3 | 318 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03106779 | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | completed | Phase 3 | 233 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 18, 2026 | clinicaltrials |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma(FIGHT-302) | terminated | Phase 3 | 167 | Incyte CorporationINDUSTRY | 19 | Aug 11, 2026 | clinicaltrials |
| NCT04685135 | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation(KRYSTAL-12) | active not recruiting | Phase 3 | 453 | Mirati Therapeutics Inc.INDUSTRY | 24 | Aug 11, 2026 | clinicaltrials |
| NCT04739761 | A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer(DESTINY-B12) | active not recruiting | Phase 3 | 506 | AstraZenecaINDUSTRY | 18 | Aug 11, 2026 | clinicaltrials |
| NCT05303532 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab(ROSY-D) | enrolling by invitation | Phase 3 | 214 | AstraZenecaINDUSTRY | 31 | Aug 11, 2026 | clinicaltrials |
| NCT05952557 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)(CAMBRIA-2) | active not recruiting | Phase 3 | 5,511 | AstraZenecaINDUSTRY | 44 | Aug 10, 2026 | clinicaltrials |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | recruiting | Phase 2 / Phase 3 | 600 | Bristol-Myers SquibbINDUSTRY | 28 | Aug 10, 2026 | clinicaltrials |
| NCT03049189 | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients(COMPETE) | active not recruiting | Phase 3 | 324 | ITM Solucin GmbHINDUSTRY | 14 | Aug 7, 2026 | clinicaltrials |
| NCT04099251 | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma(CheckMate76K) | active not recruiting | Phase 3 | 790 | Bristol-Myers SquibbINDUSTRY | 20 | Aug 7, 2026 | clinicaltrials |
| NCT02453282 | Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)(MYSTIC) | active not recruiting | Phase 3 | 1,118 | AstraZenecaINDUSTRY | 17 | Aug 6, 2026 | clinicaltrials |
| NCT05261399 | Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment(SAFFRON) | active not recruiting | Phase 3 | 341 | AstraZenecaINDUSTRY | 27 | Aug 6, 2026 | clinicaltrials |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer(IDeate-Lung02) | recruiting | Phase 3 | 540 | Daiichi SankyoINDUSTRY | 23 | Aug 6, 2026 | clinicaltrials |
| NCT03765918 | Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | active not recruiting | Phase 3 | 714 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Jul 31, 2026 | clinicaltrials |
| NCT02632409 | An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer(CheckMate 274) | completed | Phase 3 | 709 | Bristol-Myers SquibbINDUSTRY | 30 | Jul 30, 2026 | clinicaltrials |
| NCT03970447 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma(GBM AGILE) | recruiting | Phase 2 / Phase 3 | 2,250 | Global Coalition for Adaptive ResearchOTHER | 6 | Jul 30, 2026 | clinicaltrials |
| NCT05417789 | Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)(TANGENT) | active not recruiting | Phase 3 | 128 | SynOx Therapeutics LimitedINDUSTRY | 12 | Jul 29, 2026 | clinicaltrials |
| NCT06413498 | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma(iMMagine-3) | active not recruiting | Phase 3 | 452 | Kite, A Gilead CompanyINDUSTRY | 15 | Jul 29, 2026 | clinicaltrials |
| NCT07106762 | Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 29, 2026 | clinicaltrials |
| NCT06097728 | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma(eVOLVE-Meso) | active not recruiting | Phase 3 | 863 | AstraZenecaINDUSTRY | 21 | Jul 28, 2026 | clinicaltrials |
| NCT00379340 | Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor | completed | Phase 3 | 395 | Children's Oncology GroupNETWORK | 7 | Jul 24, 2026 | clinicaltrials |
| NCT03975647 | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | active not recruiting | Phase 3 | 466 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 20 | Jul 23, 2026 | clinicaltrials |
| NCT06012435 | A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 762 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Jul 23, 2026 | clinicaltrials |
| NCT03762018 | BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma(BEAT-meso) | completed | Phase 3 | 400 | ETOP IBCSG Partners FoundationNETWORK | 6 | Jul 22, 2026 | clinicaltrials |
| NCT04303780 | Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). | completed | Phase 3 | 345 | AmgenINDUSTRY | 23 | Jul 22, 2026 | clinicaltrials |
| NCT04404283 | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL(ECHELON-3) | active not recruiting | Phase 3 | 239 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 14 | Jul 22, 2026 | clinicaltrials |
| NCT05253651 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer(MOUNTAINEER-03) | recruiting | Phase 3 | 400 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Jul 22, 2026 | clinicaltrials |
| NCT05735834 | Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients(RITZ) | active not recruiting | Phase 3 | 122 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 8 | Jul 22, 2026 | clinicaltrials |
| NCT04768972 | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) | active not recruiting | Phase 3 | 89 | Ionis Pharmaceuticals, Inc.INDUSTRY | 16 | Jul 21, 2026 | clinicaltrials |
| NCT07218809 | AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer(TREVI-OC-01) | recruiting | Phase 3 | 1,100 | AstraZenecaINDUSTRY | 24 | Jul 21, 2026 | clinicaltrials |
| NCT05429632 | Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT(MO-TRANS) | recruiting | Phase 3 | 366 | Priothera SASINDUSTRY | 14 | Jul 17, 2026 | clinicaltrials |
| NCT06788990 | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC(FORTIFI-HN01) | recruiting | Phase 2 / Phase 3 | 650 | Bicara TherapeuticsINDUSTRY | 26 | Jul 17, 2026 | clinicaltrials |
| NCT07149649 | Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 / Phase 3 | 230 | Swiss Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer(OlympiA) | active not recruiting | Phase 3 | 1,837 | AstraZenecaINDUSTRY | 24 | Jul 14, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials